A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Recruiting

Phase 3

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer PatientsA Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Sponsor:

Jina Pharmaceuticals Inc.

Code:

NCT03671044

Conditions

Triple Negative Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Nanosomal Docetaxel Lipid Suspension (75 mg/m2)

Nanosomal Docetaxel Lipid Suspension (100 mg/m2)

Taxotere® (100 mg/m2)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Jina Pharmaceuticals Inc. on 2025-03-25.